Clinical Trials Logo

Benign Prostatic Hyperplasia clinical trials

View clinical trials related to Benign Prostatic Hyperplasia.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06424912 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Vivifi's Treatment, BPH Treatment Via Vasculature Anastomosis

Start date: August 30, 2024
Phase: N/A
Study type: Interventional

The study objective is to evaluate the safety and feasibility of the Vivifi's Treatment. The Vivifi's Treatment presents an innovative approach for addressing benign prostatic hyperplasia (BPH) as well as clinical/subclinical varicoceles in men. The scientific rationale for conducting this study is to assess the safety and feasibility of the Vivifi's Treatment (a surgical procedure) as a therapeutic intervention for patients with BPH.

NCT ID: NCT06275256 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Outcomes of MIST for BPH: A Single-Institution Prospective Study

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile.

NCT ID: NCT06212453 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Evaluation of the Functional Outcomes After Bilateral, 3D Ultrasound-guided Focal Thermal Ablation of the Prostate Transition Zone, in Patients With Benign Prostatic Hyperplasia-related Obstruction

BETTANY
Start date: April 2024
Phase: Phase 2
Study type: Interventional

The aim of the current study is to evaluate the efficacy of transperineal focal microwave ablation (TMA) of the prostate transition zone as a new treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) within a prospective single-institutional pilot study.

NCT ID: NCT05913466 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Intraprostatic Injection of Tranexamic Acid Decrease Blood Loss During Monopolar TURP

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

This study aims to assess the role of intraprostatic injection of tranexamic acid in decreasing the blood loss during Transurethral resection of the prostate.

NCT ID: NCT05784909 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Outcomes of Water Vapor Thermal Therapy (REZUM) in Management of Symptomatic Patients With Benign Prostatic Enlargement

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

new treatment modality for BPH , less invasive and more effective.

NCT ID: NCT05784558 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up

RELIEF
Start date: April 3, 2023
Phase:
Study type: Observational

The objective of the RELIEF Study is to compare the safety, effectiveness and patient experience outcomes in real-world subjects treated with different modalities for symptomatic BPH.

NCT ID: NCT05576311 Not yet recruiting - Clinical trials for Urinary Incontinence

Codesign of an Optical Device to Measure Urine Flow and Volume

Start date: November 1, 2022
Phase:
Study type: Observational

The study is seeking to understand the needs of patients and healthcare practitioners for an innovation in the way that changes in bladder function are assessed. This information will be used in the design and evaluation of a device, being developed in parallel, that assesses changes to the volume and flow of urine in order to determine changes in bladder function. In order to ensure development is optimal, the principal research objective is therefore to understand the needs of patients and healthcare practitioners (ranging from care home staff and GPs in primary care, to urologists in tertiary referral centres).

NCT ID: NCT05567666 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)

SUMMIT
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.

NCT ID: NCT05393921 Not yet recruiting - Overactive Bladder Clinical Trials

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

Start date: November 30, 2024
Phase: Phase 4
Study type: Interventional

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life. Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints. Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart). The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated. The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively. The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

NCT ID: NCT05306145 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Comparison of H-FIRE and TURP in Treating Benign Prostatic Hyperplasia

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This trial is comparing the effects and safety in treating men with benign prostatic hyperplasia between high freqnence irreversible electroporation and trans urethral resection prostate.